Literature DB >> 25601962

Breaking down the evidence for bevacizumab in ovarian cancer.

Catherine A Shu1, Jason A Konner2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25601962      PMCID： PMC4319628          DOI： 10.1634/theoncologist.2014-0302

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  18 in total

1.  Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer.

Authors:  Martin R Stockler; Felix Hilpert; Michael Friedlander; Madeleine T King; Lari Wenzel; Chee Khoon Lee; Florence Joly; Nikolaus de Gregorio; José Angel Arranz; Mansoor Raza Mirza; Roberto Sorio; Ulrich Freudensprung; Vesna Sneller; Gill Hales; Eric Pujade-Lauraine
Journal:  J Clin Oncol       Date:  2014-03-31       Impact factor: 44.544

2.  Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer.

Authors:  Bradley J Monk; Ernest Han; Carol A Josephs-Cowan; Gordon Pugmire; Robert A Burger
Journal:  Gynecol Oncol       Date:  2006-06-21       Impact factor: 5.482

3.  Detecting an overall survival benefit that is derived from progression-free survival.

Authors:  Kristine R Broglio; Donald A Berry
Journal:  J Natl Cancer Inst       Date:  2009-11-09       Impact factor: 13.506

Review 4.  Tumor angiogenesis: therapeutic implications.

Authors:  J Folkman
Journal:  N Engl J Med       Date:  1971-11-18       Impact factor: 91.245

5.  Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia.

Authors:  Agustin A Garcia; Hal Hirte; Gini Fleming; Dongyun Yang; Denice D Tsao-Wei; Lynda Roman; Susan Groshen; Steve Swenson; Frank Markland; David Gandara; Sidney Scudder; Robert Morgan; Helen Chen; Heinz-Josef Lenz; Amit M Oza
Journal:  J Clin Oncol       Date:  2008-01-01       Impact factor: 44.544

6.  Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial.

Authors:  Noriyuki Katsumata; Makoto Yasuda; Fumiaki Takahashi; Seiji Isonishi; Toshiko Jobo; Daisuke Aoki; Hiroshi Tsuda; Toru Sugiyama; Shoji Kodama; Eizo Kimura; Kazunori Ochiai; Kiichiro Noda
Journal:  Lancet       Date:  2009-09-18       Impact factor: 79.321

7.  Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer.

Authors:  Stephen A Cannistra; Ursula A Matulonis; Richard T Penson; Julie Hambleton; Jakob Dupont; Howard Mackey; Jeffrey Douglas; Robert A Burger; Deborah Armstrong; Robert Wenham; William McGuire
Journal:  J Clin Oncol       Date:  2007-11-20       Impact factor: 44.544

8.  Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study.

Authors:  Robert A Burger; Michael W Sill; Bradley J Monk; Benjamin E Greer; Joel I Sorosky
Journal:  J Clin Oncol       Date:  2007-11-20       Impact factor: 44.544

Review 9.  Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis.

Authors:  Sanjaykumar Hapani; David Chu; Shenhong Wu
Journal:  Lancet Oncol       Date:  2009-06       Impact factor: 41.316

10.  Bevacizumab 5 mg/kg can be infused safely over 10 minutes.

Authors:  Diane L Reidy; Ki Y Chung; John P Timoney; Vivian J Park; Ellen Hollywood; Nancy T Sklarin; Raymond J Muller; Leonard B Saltz
Journal:  J Clin Oncol       Date:  2007-07-01       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.